© Copyright Nostre Net
Market Highlights
Downstream processing refers to the series of operations required to derive pure and homogeneous protein products from biological materials such as cells, tissue culture fluid, or plant tissues. There is a high demand for the end products extracted by downstream processing, owing to the increasing applicationsin biopharmaceutical products. Thus, the downstream processing market trends is anticipated to observe significant growth during the forecast period.
According to MRFR analysis, the global downstream processing market growth is expected to register a CAGR of~16.09% from 2021 to 2027and hold a value of ~USD 61,174.53million by 2027.
Key Players
Some of the key players in the global downstream processing market are Thermo Fisher Scientific Inc. (US), Sartorius Stedim Biotech S.A. (France), Merck Millipore (Germany), Danaher Corporation (US), 3M Company (US), Boehringer Ingelheim (Germany), Lonza Group AG (Switzerland), Eppendorf AG (Switzerland), Corning Incorporated (US), and Asahi Kasei Corporation (Japan).
Segmentation
The global downstream processing market has been segmented into technique, product, application, and end user.
By technique, the market has been segregated into cell disruption, solid-liquid separation, clarification/concentration, purification techniques, and formulation. The purification techniques segment is further sub-segmented into ion exchange, affinity exchange, hydrophobic interaction, size exclusion chromatography, and others. The purification techniques segment held a significant share of the market in 2020, as it isone of the vital steps in downstream processing and has high product differentiation.
Based on the product, the global downstream processing market has been classified as chromatography columns &resins, filters, membrane adsorbers, and others. The chromatography columns &resinsis one of the most widely used product andwasestimated to bethe largest segment in 2020.
Based on application, the downstream processing market is segmented into antibiotic production, hormone production, antibodies production, vaccine production, and others. Antibiotic productionis one of the vital applications owing to increasing infectious diseases. Furthermore, the ongoing pandemic has created a huge demand for vaccine production globally which further supports the growth of the market.
Based on the end user, the downstream processing market is segmented into biopharmaceutical manufacturers, contract manufacturing organizations, and others. The biopharmaceutical manufacturers segment held the largest market share in 2020 due to increased R&D activities and production of biologics at a largescale, along with the rapidly growing biopharmaceutical industry.
Regional Analysis
By region, North America is anticipated to dominate the global downstream processing market, owing to well-established research organizations involved in research activities, the presence of a high number of contract manufacturing organizations (CMOs), and the presence of a largenumber of pharmaceutical and biopharmaceutical companies. Moreover, the rise in R&D investments by public and private players in the healthcare sectorfurther drives the market growth.
On the other hand, the European downstream processing market is driven by rising R&D expenditure by biopharmaceutical companies, increasing investments in the R&D sector, and the presence of key market players. For instance, in November 2019, Thermo Fisher Scientific, Inc. (US) announced that it is investing nearly USD 24 million in its Scotland site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.
Asia-Pacific is anticipated to be the fastest-growing market in the region over the assessment period due to growing and improving healthcare infrastructure, the establishment of research organizations, and increasing investments in biotechnology. In addition, factors such as the growing investments by key market players and the rapidly developing pharma and biopharma sector in the region are further driving the market.For instance, in April 2021, Asahi Kasei Corporation, a solution provider to the biologics manufacturing industry, expanded its business in China with the launch of Asahi Kasei Bioprocess (Shanghai) Co., Ltd (AKBC).The launch of AKBC facilitates business expansion in China by localizing inventory management and order processing for shorter delivery times.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Overview:
Molecular modelling is a strategy that involves computational techniques that integrates creation, manipulation, and representation of molecular structures. Based on this technology, a lot of drug can be developed. This process enables scientists to run various simulations that can ensure better results for the global drug development market. The global molecular modelling market share can achieve a CAGR of 15.93% during the forecast period 2027. Market Research Future (MRFR) discloses possibilities that can be explored well in the future to ensure strong growth in the coming years.
Various factors like hike in research-related investments, growing impact from pharmaceuticals to discover new drugs, technologies to develop personalized drug, better healthcare-related investments, growing cases of chronic disease, hike in budgets for healthcare sector, and other are expected to influence the global molecular modelling market. The burgeoning biosimilars and biologics industry is expected to take the market further ahead in the coming years.
Segmentation:
Product, application, and end-users are segments that have been included in the global molecular modelling market. This analysis is expected to provide in-depth analysis of various factors that can be used later to garner more profits in the coming years.
By product, the molecular modelling market comprises software and services. The software segment is generating substantial revenue and is expected to climb up with a 13.55% CAGR. But the services segment is expected to register the fastest CAGR of 18.64% within the same time frame.
Based on the application, the global molecular modelling market can be segmented into drug development, drug discovery, and others. the drug development segment can step ahead with 13.26% CAGR during the forecast period. The drug discovery segment is deemed to register the fastest CAGR of 17.30% over the assessment period.
By end-users, the molecular modelling market comprises research centers & academic institutions, pharmaceutical & biotechnological companies, and others. The pharmaceutical and biotechnological companies are expected to register a 13.84% growth during the forecast period, whereas, the research centers and academic institutions can post a CAGR of 19.16% during the review period.
Regional Analysis:
Region-wise analysis of the global molecular modelling market has four specific regions under its coverage. These regions are the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA). The report is all set to provide better demographic analysis to assist in the exploration of several possibilities that can impact the market growth in the future.
Technical superiority, robust infrastructure, high expenditure capacity, better research & development projects, and other healthcare-related initiatives are expected to provide strong traction to the regional market. The Americas is a region that includes two regions, North and South America. North America has better market scenario than South America.
Europe is sharing similar features like that of North America. These two regions are known for their research and development projects where development of new products and innovations are quite expected. The region is following North America closely in terms of market valuation. Several countries like the UK, France, Germany, and others are expected to promote the regional market.
The APAC market is expecting strong growth in the coming years with assistance from the hike in the market valuation of China, India, Thailand, Singapore, and others.
Competitive Landscape:
Prominent market players in the global molecular modelling market are Schrödinger, LLC, Cresset, Acellera Ltd., BioSolve-IT, Optibrium, Chemical Computing Group, Simulations Plus, Inc., Cambridge Crystallographic Data Centre OpenEye Scientific Software, Certara, L.P, Dassault Systèmes, and others. MRFR included these companies and profiled them for a better analysis of the global process. Such a report also includes various strategic moves taken by these companies. These moves are merger, acquisition, collaboration, and other methods.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
The global biopharmaceutical excipients market is driven by several factors, such as increasing demand for oral formulations across the globe, rising demand for customized medicines, and an increasing geriatric population. Other factors such as increasing patients with chronic ailmentscoupled with growing life expectancy are driving the production of biopharmaceuticals. In addition, increasing stress, back pains, body aches, and headaches has augmented the demand for topical type formulation, accelerating the market growth.
According to MRFR analysis, the global biopharmaceutical excipients market Growth is expected to register a CAGR of~6.8% from 2021 to 2027and is expected to hold a value of ~USD 3,114.6 million by 2027
The industry players focus on expanding their global footprint by strategic partnerships, investing in some company’s stock, acquisitions, and product launches. For instance, in February 2020, ReForm Biologics (US) partnered with MilliporeSigma (US) to commercialize excipients used in biotherapeutics. In August 2019, LBB Specialties (US) announced the strategic partnership with MEGGLE (Germany)to expand its excipient distribution channel across the US. In December 2018, Roquette (France) bought a majority stake in excipient producer Crest Cellose (India) that enabled the company to expand its product portfolio and presence in the Indian generic pharmaceutical market. Furthermore, the prominent players focus on new developments, employee satisfaction, the transformation of their research wings, and expanding their distribution network. These factors will augment the market growth and will increase theproduct demand in the forecast timeline.
Key Players
Some of the key players in the global biopharmaceutical excipients market are Merck KGaA (Germany), Colorcon (BPSI Holdings Inc) (US), BASF SE(Germany), Associated British Foods plc (UK), Signet Excipients Pvt. Ltd (IMCD) (Netherlands), Sigachi Industries Limited (Hyderabad), Spectrum Chemical Manufacturing Corp. (US), Roquette Frères (France), Clariant (Switzerland), DFE Pharma (Germany), J. Rettenmaier & Söhne Gmbh + Co Kg (Germany), and Evonik Industries AG (Germany).
Regional Analysis
North America is projected to dominate the biopharmaceutical excipients market due to the growing adoption of the latest drug manufacturing technologies, increasing chronic diseases, and expansion of production capabilities of the industry players across the region. In addition, highinvestments were made in the development of new excipient variants to advance the product portfolio. Furthermore, the key players are involved in collaborations, mergers, and R&D activities that propel market growth.
Europe embraces the second-largest position in the biopharmaceutical excipients market due to growing investments in the pharmaceutical sector and increasing production capacity across the region. In addition, the region experienced high demands for pharmaceutical products. Moreover, countries such asGermany, Italy, the UK, France, and Spain have invested huge amounts in the manufacturing of new vaccines.
Asia-Pacific is anticipated to be the fastest-growing regional market over the projected timeline due to the rising investment in pharmaceutical research and production facilities, increasing consumption of medicines, and supportive government alliances and subsidy schemes. In addition, the availability of highly skilled research employees and an economical workforce is creating opportunities for the industry players.
Furthermore, the market in the Rest of the World is gaining importance due to the rising number of investors, growing geriatric population in countries such as Chile and Argentina, and expansion of the pharmaceutical market across Latin America. However, the availability of counterfeit pharmaceutical goods is hampering the biopharmaceutical excipient market. The pharmaceutical companies aim atinvesting in the Middle East & Africaregion owing to its technologically advanced labs and other research infrastructures. Countries such as Saudi Arabia and the UAE are hiring employees throughout the globe to advance their pharmaceutical market.
Segmentation
The global biopharmaceutical excipients market is categorized into product and formulation. Based on the product category, the market has been segregated into solubilizers & surfactants/emulsifiers, polyols and carbohydrates, and specialty excipients. The carbohydrates segment is expected to hold a considerable share of the market in 2021. Increasing R&D activities for the development of lipid and protein excipient-based corona vaccines is fueling the market demand. In addition, the high demand for carbohydrate-based medicines for the infant segment is propelling the biopharmaceutical excipient market.
Based on formulation, the global biopharmaceutical excipients market has been classified as oral, topical, and injectables. The oral segmentheld the major share in 2020 due to the easy intake procedure and availability of oral medicines throughout the hospitals and retail stores. Additionally, the demand for oral and topical formulations is accelerating due to the growing preference for on-the-go treatment and ambulatory treatment services coupled with increasing cases of trypanophobia.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Overview
Tissues, cell lines, and cells are tested, characterized, stored, and collected by the cell banking outsourcing industry. These activities are carried out to aid in the production of biopharmaceuticals as well as research and development activities, ensuring minimal side effects and great efficacy. The technique for cell preservation entails initially proliferating cells, which subsequently multiply into a large number of identical cells, which are then stored in cryovials for future use. The production of regenerative medicine is essentially based on the use of cells. During the projection period of 2021 to 2027, the cell banking outsourcing market is estimated to reach USD 9476.9 million, growing at a CAGR of 15.6%.
Market Trends
During the forecast period, the cell banking outsourcing market growth is expected to rise due to an increase in the number of cell banks around the world. Another factor projected to drive market growth is the growing number of applications of cell-based products for research and therapeutics. Furthermore, a jump in the number of start-ups focusing on cell-based therapeutics and vaccine production is expected to drive market expansion. Similarly, the growing emphasis on regenerative and customized medicine is expected to fuel growth in the cell banking outsourcing industry. Due to well-established healthcare infrastructure, large patient populations, and significant healthcare expenditures, several key businesses focus on tailoring products and services to the American and European markets. There are no public cord blood banks in Africa, and importing cord blood units from other countries is prohibitively expensive for most patients. With first-to-market advantage, launching subsidiaries in developing regions can be advantageous.
Competitive Dynamics
The notable players of the market are CordLife (Singapore), Cleancells (France), Charles River Laboratories (US), BSL Bioservice (Germany), BioReliance (US), Sartorius (Germany), Covance (US), LifeCell International Pvt. Ltd. (India), Goodwin Biotechnology Inc. (US), GlobalStem Inc. (US), Cryo-Cell International Inc. (US), Lonza (Switzerland), PX’TherapeuticsSA (France), Wuxi Apptec (China), and the SGS fe Sciences (Switzerland).
Segmental Analysis
The global cell banking outsourcing market is divided into three categories: bank, cell, and application.
The market has been classified into three categories based on bank type: master cell banking, working cell banking, and viral cell banking. Because of its widespread utility, master cell banking is expected to have the largest market share in the worldwide cell banking outsourcing market.
The cell banking outsourcing market has been divided into stem cell banking and non-stem cell banking based on cell type. Because of its growing uses in regenerative medicine, the stem cell banking sector is expected to have the greatest market share in 2021.
Cell bank storage, cell bank preparation, and bank characterization and testing are the application segments of the cell banking outsourcing market.
Regional Overview
North America, Europe, Asia-Pacific, and the rest of the globe are the regions that make up the market.
Because of the greater adoption rates of novel technologies for the manufacturing of vaccines and therapeutic antibodies, North America is expected to have the greatest market share in 2021. Furthermore, the presence of various biopharmaceutical businesses in the region is expected to drive the cell banking outsourcing market in North America to new heights in the near future. North America is also likely to be a lucrative market due to the large number of research and development initiatives related to cytological inquiry for proteomics, genomics, and medication and vaccine development currently underway in the region. The growing demand for vaccines and biopharmaceuticals is expected to boost this region's growth.
Overview
Cellulite production has swelled in recent years due to poor nourishment, static postures, dehydration, inflammation, eating habits, alcohol intake, among other factors. The MRFR report predicts that the market will earn a revenue level of USD 1,086.44 million at a CAGR of 8.97% by 2027.
Most corporate employees with cellulite are working on their wellbeing and fitness to amplify their productivity. Resultantly, many firms are partnering with clinics and hospitals to help their staff stay healthy. The cellulite treatment market size is motivated by the tremendous influx of female population in metro centers due to employment as younger employees are more health-conscious and press for a better physique to avoid medical problems.
The foremost players in the cellulite treatment market are Nubway (China), Zimmer Aesthetics (Germany), Skinrex Co., Ltd. (South Korea), Cymedics (Germany), Tanceuticals, LLC. (US), Cynosure, Inc. (US), Inceler Medikal Co. Ltd. (Turkey), Syneron Medical Inc (US), Hologic Inc. (US), Cutera (US), Beijing Sincoheren S & T Development Co., Ltd, (China), Candela Medical (US), and Merz Pharma GmbH & Co. KGaA (Germany).
Segmental Analysis
The segmentation of the cellulite treatment market has been conducted based on cellulite type, treatment procedure, region, and end use. The cellulite treatment market is divided into three segments based on end use: specialized dermatological clinics, hospitals, and ambulatory surgical centers. The cellulite treatment market has been segmented based on treatment procedures into minimally invasive, non-invasive, and topical treatment. The cellulite treatment market has been divided into three segments based on cellulite type: soft cellulite, hard cellulite, and edematous cellulite. The region segment of the cellulite treatment market includes North America, Asia-Pacific, Europe, and other important regions.
Detailed Regional Analysis
The regional assessment of the cellulite treatment market includes North America, Asia-Pacific, Europe, and other important regions. North America will have the greatest cellulite treatment market share in 2020, owing to well-established product development research groups, the availability of novel treatment products, the consumption of unhealthy diets, and the significant desire for the sculpted figure. The primary players are expanding their operational facilities across the region, collaborating in collaborations and partnerships, and launching new products to drive economic interests. Due to the transformation of healthcare infrastructure, the construction of R&D facilities, and increased awareness about body contouring and physical wellness, the Asia-Pacific cellulite treatment market is estimated to be the fastest regional market.
Competitive Analysis
The continuation of occasional lockdowns in numerous regions may cause the market expansion to be hampered if resources such as labor and supply chains are severely impacted. The global market is expected to diversify in operational techniques as innovative models for operation and delivery are implemented. Government assistance is expected to support worldwide market development in the next years. Due to the return of COVID cases in many locations, the market may exhibit constrained growth. It is projected that the emphasis on accumulating reserves of resources to deal with unexpected crises would impact future market trends. Market developments and research are expected to generate attractive growth opportunities in the next years. The reliance on online commerce for sales is expected to increase significantly during the forecast period, prompting market stakeholders to invest more in its growth.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Insights
Healthcare research and the high demand for food are key areas where next-generation sequencing is being used extensively. Increasing genetic disorders are being diagnosed which has drastically increased the demand for next-generation sequencing. Moreover, the use of this technology in drug discovery is significant and expected to drive growth as the demand for effective drug therapies increases.
global Next-Generation Sequencing Market is expected to increase value of USD 10300 million during the projected quarters of 2022-2030, The market is estimated to grow at 11.5% CAGR by 2030. Also known as massive parallel sequencing or high throughput sequencing technology, next-gen sequencing has been transformative for the field of genomic research as it allows the sequencing of a complete human genome in a very short amount of time. During the process, the genetic material is extracted, fragmented, and associated with various factors for amplification. As such, this technology is highly effective and advanced thus driving its adoption and growth. The improved speed and reduced costs are expected to drive market growth. Use in clinical applications, agricultural applications, and forensic applications are growing rapidly.
Increasing awareness, employment of various growth strategies and ongoing technical advancements are expected to provide the market with ample opportunity for growth. However, the high initial cost of implementing technologies, and the requirement for storage of large volumes of data as well as a lack of skilled workforce to run the technology are challenges to the growth of the Next Generation Sequencing market.
Key Players
Oxford Nanopore Technologies, Ltd., BGI, Pacific Biosciences of California, Inc., PerkinElmer, QIAGEN N. V., Eurofins Scientific, Agilent Technologies, Macrogen Inc, Illumina, Inc., and Thermo Fisher Scientific, Inc. are among the notable market players that have been included in MRFR’s competition tracking of the global next generation sequencing market.
Market Segmentation
Analysis of the markets several parts are included in MRFR's segmental analysis which has been performed on the basis of technology, service & product, application, end-user, and region.
The technology used in next-generation sequencing includes whole exome sequencing, CHIP sequencing, whole genome sequencing, methyl sequencing, targeted resequencing, de novo sequencing, and RNA sequencing, next generation sequencing data analysis.
By service & product, the next generation sequencing market has been segmented into consumables, sample preparation, platforms & services for platforms, and sequencing services. The sample preparation segment is further divided into end repair, A-tailing & size selection, quality control, library preparation & target enrichment, and DNA fragmentation. Other sub-segmentations have been mentioned and expounded on in the report.
Applications of next-generation sequencing include genetic screening, drug discovery, diagnostics, agriculture & animal research, and others.
End-users of next-generation sequencing include hospitals & clinics, academic institutes & research centers, pharmaceutical & biotechnology companies, and other end-users.
Regional Analysis
The global next generation sequencing market is segmented into key regions which include the Americas, Asia Pacific, Europe, and the Middle East & Africa. North America in the Americas region is slated to lead the market with the largest share due to the high competition between market players in the region as well as the rising demand for next-gen sequencing in the healthcare sector of developed economies such as the US and Canada. Moreover, the presence of a significant healthcare sector in the region combined with growing investments in healthcare toward the development of therapies for chronic diseases will push growth during the forecast period.
The European region has the second largest market due to the significant R&D activities that take place in the region with regards to various fields including healthcare. The presence of pioneering next-gen sequencing technology market players are expected to make an impact on the market. However, growth here is restrained due to regulations and fragmentation of the market across Europe.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Cerebral palsy is defined as a group of disorders that affect muscle movement and coordination, which in many cases, impairs vision, hearing, sensation and others senses. Cerebral palsy is a congenital disorder of movement, muscle tone or posture and can affect a person’s posture, balance and ability to move, communicate, eat, sleep and learn. According to the Centre for Disease Control 1 to 4 out of every 1,000 children across the globe are affected by cerebral palsy, thereby creating a strong demand for dia gnosis, and treatment for the condition which will drive growth for cerebral palsy market.
The cerebral palsy market is anticipated to reach USD 3,287.51 Million by 2030 at 3.20% CAGR during the forecast period 2022-2030.
Competitive Overview:
Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd. are some of the key players in the global cerebral palsy market.
Segmentation
The cerebral palsy market has been segmented into type, diagnosis, and treatment.
On the basis of type, cerebral palsy market has been segmented into hypotonic cerebral palsy, spastic cerebral palsy, ataxic cerebral palsy, dyskinetic cerebral palsy, and mixed cerebral palsy.
By diagnosis, CP market segmentation includes imaging tests and others. The imaging tests segment has been further classified into computed tomography, magnetic resonance imaging (MRI), cranial ultrasound, and electroencephalogram.
Based on treatment, cerebral palsy market has been segmented into therapy, medication, surgery, cerebral palsy drugs and others.
Regional Market Summary
Geographically, the Americas region is anticipated to dominate the global cerebral palsy market owing to a well-developed healthcare sector, rising prevalence of cerebral palsy and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region and a relatively large number of research and development (R&D) activities contributes to the growth of the market.
Europe is expected to hold the second largest position in the global cerebral palsy market. The market growth in this region is attributed to the growing prevalence of cerebral palsy, availability of funds for research, and increasing healthcare expenditure. According to the data stated by the National Institute for Health and Care Excellence (NICE) in 2017, in the UK, it is estimated that 1 in 400 babies are born with cerebral palsy. It also stated that approximately 1,800 children diagnosed with CP each year.
The cerebral palsy market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of cerebral palsy and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Overview:
The global nutraceutical excipients market is growing pervasively. The market growth is mainly driven by the burgeoning nutraceutical sector. In 2017, the market had reached USD 3104.96 Mn and is expected to value at USD 4818.70 Mn. by 2023. Excipients are inactive components added to nutraceuticals during its production to help stabilize the ingredients. Nutraceutical excipients perceive augmenting demand, which in turn, substantiates its market size globally.
Hike in investment related to healthcare, transforming lifestyle triggering various diseases, and others are major factors that can significantly inspire the growth rate of the market. The growing awareness among people regarding health benefits, an increasing number of products entering the pipeline, and others can inspire the growth of the market. On the other hand, stringent regulations can hold back the growth rate in the coming years. But the market can bank on the developing technologies for better growth assistance.
Competitive Landscape:
A lot of companies are trying to make the market for the global nutraceutical excipients prosper with high growth opportunities. These segments are known for extensive participation in taking the market ahead. MRFR recorded their recent steps to gauge in which direction the market is moving and find better growth possibilities there. These companies are Ingredion, Cargill Corporation, Kerry, Sensient Technology Corporation, Associated British Foods plc, JRS PHARMA, Roquette Freres SA, DowDupont, Innophos, Inc., and Hilmar Ingredients.
Segmentation:
The global market for nutraceutical excipients is set to find a segmentation in the report that would be based on form, function, type, and application. These segments have a better acceptance of various factors that can be taken into consideration to understand how the market can chart the future path.
By function, the market for nutraceutical excipients can be segmented into fillers, diluents & bulking agents, disintegrants, binders, lubricants, sweeteners, coating agents, and colors & flavors. The fillers, diluents & bulking agents have a chance to expand at 8.34% CAGR during the forecast period.
By form, the market for nutraceutical excipients can be segmented into liquid and dry. The former has a better market share. It has a coverage of almost 55% of the global market. It had a market valuation of USD 1 Bn in 2017. The dry segment can score a 7.34% CAGR during the review period.
By application, the market for nutraceutical excipients can be segmented into omega-3 fatty acids, proteins & amino acids, probiotics & prebiotics, and vitamins & minerals. The probiotics & prebiotics segment had the market command in 2017 when it had coverage of 47.5% market share. Its CAGR would be impressive. However, the vitamins & minerals segment has the chance for growth with a CAGR of 7.92% during the forecast period.
By type, the market report that includes nutraceutical excipients can be segmented into artificial and natural/organic. The artificial segment had better market dominance in 2018. But growing consumer awareness can inspire a better intake of the natural/organic nutraceuticals products.
Regional Analysis:
The Americas have a high chance of contributing the maximum revenues in terms of fetching from the profit. The regional market has North and South America. North America includes the US and Canada where various global nutraceutical excipients market players are gaining hike from increasing chronic diseases, high health-related investment, better awareness, assistance from various policies, and others are expected to create better provision for the global market. Various changes in the lifestyle have influenced a hike in various diseases like diabetes, respiratory issues, and others. The market in Europe is expected to establish itself as the second-best market. Its resemblance to North America can inspire better market growth. Health cost expenditure in the region is quite high owing to which the market can witness better growth. Its intake as a preventive measure is quite high in the region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Drivers and Key Barriers
Optical imaging refers to a technology that holds great potential to improve the mode of treatment, disease diagnosis, and prevention in the hospital operating room. This technology offers a host of benefits compared to radiological imaging techniques. Optical imaging technique makes use of non-ionizing radiation and reduces the patient’s radiation exposure, which gives way to numerous studies over time. It also helps differentiate soft tissues from native soft tissues or the tissues that posses exogenous or endogenous contrast media using various photon absorption profiles at different wavelengths. Optical imaging is a highly responsive imaging technique which can be used by easily combining it with other imaging techniques.
The optical imaging market is expected to be of value USD 3.44 billion in 2030 and to grow at a 9.7% CAGR during the forecast 2022-2030.
Pharmaceutical and biomedical industries make heavy demand for radiation-free imaging techniques, which accelerates the popularity of optical imaging. Surging prevalence of neurological as well as ophthalmological disorders among the worldwide population could accelerate demand for imaging diagnosis, thereby elevating market growth. Technological advancement coupled with increasing government support that benefits the healthcare industry paves the way for several growth opportunities.
Some other growth-inducing factors driving market growth include quick adoption rates of technically advanced devices, highly-developed research infrastructure, and growing number of skilled professionals. Technological advancement has led to complete transformation of medical science, where optical imaging stands as the most affected aspect. This has revolutionized the healthcare industry by increasing the ability to detect a higher number of diseases.
Market Segmentation
The worldwide market for optical imaging has been segmented on the basis of products, techniques, therapeutic area, application, and end-user.
With respect to the type of product, the market comprises imaging systems, software, lenses, illumination systems, cameras, and others. Imaging systems can be sub-segmented into optical imaging systems and spectral imaging systems.
Technique-wise, the market covers optical coherence tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
Depending on the therapeutic area, the market covers oncology, ophthalmology, neurology, cardiology, dermatology, dentistry, and others.
Considering the application, the market caters to pre-clinical and clinical research, pathological imaging, and intraoperative imaging.
The end-users in the market include hospitals and clinics, diagnostic imaging centers, pharmaceutical &biotechnology companies, and research laboratories.
Regional Insight
Based on the geographical distribution, the market for optical imaging has been studied in the primary regions of Europe, the Americas, Middle East, and Africa and Asia Pacific.
The Americas has been identified as the largest market for optical imaging. Rising prevalence of neurological, ophthalmic, and cardiovascular disorders among the geriatric population triggers market growth in the region. Moreover, a boost in the number of government initiatives along with funding for research within the medical devices sector stimulates market growth. Mounting demand for accurate diagnosis, high awareness regarding the adverse effects of radiation imaging, and presence of highly regarded pharmaceutical companies work in favor of the market. Also, vast patient pool in the region is expected to augment market demand in the years to come.
Europe stands as the second leading market for optical imaging. The robust share is the result of existence of advanced treatment facilities, high healthcare expenditure, and well-developed healthcare infrastructure. The flourishing medical device industry backed by the efforts of prominent players adds to the market strength. Plus, rising knowledge with regard to the benefits of optical imaging compared to radiation imaging spurs the market growth in the region.
Asia Pacific could expand at the fastest rate, holding the most promising growth prospects. A 2014 report by the department of neurology reveals that among the present population of 1.27 billion, close to 30 million people are afflicted with neurological disorders only in India. Therefore, the huge patient pool combined with the fast rate at the healthcare technology is catching up, the regional market is bound to note excellent gains in the near future. The region also benefits from various government initiatives that help improve healthcare quality and the availability of favorable insurance policies. Apart from this, the lower cost of clinical trials and several research companies striving to set up their regional headquarters as well as manufacturing plants in China, Singapore, Korea, Australia, and Japan could mark an optimistic market outlook in the subsequent years.
Middle East & Africa could showcase poor growth in the global market. The factors holding back the market include limited access and availability of treatment facilities and lack of awareness. In the Middle East, Saudi Arabia and the United Arab Emirates (UAE) account for the substantial share in response to the steadily expanding healthcare industry and increasing number of specialty care centers. Overall, the regional market could demonstrate consistent growth soon owing to rising number of government initiatives aimed at enhancing the quality of healthcare.
Renowned Companies
Some of the renowned companies shaping the worldwide optical imaging market are Bioptigen, Inc., Agfa-Gevaert N.V., Perkinelmer, Inc., Carl Zeiss Meditec AG, St. Jude Medical, Inc., Topcon Corporation, Heidelberg Engineering, Inc., Canon Inc., Koninklijke Philips N.V., among others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Multiplex Assays Market – Overview
The uptick in demand for nanotechnology practices that can solve several genetic-related diseases has increased of late. The multiplex assays market is expected to reach USD 3.11 Billion an approximate CAGR of 6.80% during the forecast period (2022-2030).The market for multiplex arrays is advancing due to the increased funding and research being diverted to the market. Increased awareness of the benefits of multiplex assays is fuelling the growth of the market over the forecast period. The multifactorial nature of several diseases and pathological conditions such as Alzheimer and cancer are motivating the development of the market significantly.
Segmental Analysis
The multiplex assay market is segmented on the basis of types, application, products and services, technology, and end-user. By products and services, the market is segmented into instrument, consumable, and software and services. Based on types, the market is segmented into nucleic acid, protein, and cell-based multiplex assay. On the basis of technology, the market is segmented into fluorescence detection, flow cytometry, luminescence, multiplex real-time PCR, and other technologies. On the basis of application, the market is segmented into clinical diagnostic, research and development, and other diseases. By end user, the market is segmented into hospital and research institutes, pharmaceutical and biotechnology companies, clinical laboratories, and other end-users.
Competitive Analysis
The notable contenders shaping the market development over the forecast period are Illumina Inc, Bio Rad Laboratories Inc, Thermo Fisher Scientific Inc, Qiagen, Abcam plc, BD, Agilent Technologies, Meso Scale Diagnostics LLC, Merck Sharp & Dohme Corp, Quanterix, Bio-Techne, Randox
Detailed Regional Analysis
The North America region is accountable for the prime stake of the market due to robust R&D activities in this region. The US is a chief country in terms of biopharmaceutical research and development. The important factors that drive the development of the market in this region are the rise in-patient population, and the growing detection of Alzheimer disease, and a substantial rise in research and development activities of the pharmaceutical companies for the treatment of diseases such as cancer and Alzheimer. The Asia Pacific is anticipated to record the highest CAGR during the forecast period. Due to the increasing geriatric population, mounting prevalence of cataract, and growing prevalence of Alzheimer disease in this region. The European region is estimated to note a high CAGR during the forecast period owing to the increasing geriatric population.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.